剂量探索等渗设计的比较
Comparison of Isotonic Designs for Dose-Finding.
作者信息
Ivanova Anastasia, Flournoy Nancy
机构信息
Associate Professor, Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7420.
出版信息
Stat Biopharm Res. 2009 Feb 1;1(1):101. doi: 10.1198/sbr.2009.0010.
Abstract
We compare several decision rules for allocating subjects to dosages that are based on sequential isotonic estimates of a monotone dose-toxicity curve. We conclude that the decision rule in which the next assignment is to the dose having probability of toxicity closest to target does not work well. The best rule in our comparison is given by the cumulative cohort design. According to this design, the dose for the next subject is decreased, increased, or repeated depending on the distance between the estimated toxicity rate at the current dose and the target quantile.
摘要
我们比较了几种基于单调剂量-毒性曲线的序贯等渗估计将受试者分配到不同剂量的决策规则。我们得出结论，下一次分配到毒性概率最接近目标值的剂量的决策规则效果不佳。我们比较中最佳的规则由累积队列设计给出。根据此设计，下一个受试者的剂量根据当前剂量下估计的毒性率与目标分位数之间的距离而降低、增加或重复。
相似文献
1
Comparison of Isotonic Designs for Dose-Finding.剂量探索等渗设计的比较
Stat Biopharm Res. 2009 Feb 1;1(1):101. doi: 10.1198/sbr.2009.0010.
2
Revisiting isotonic phase I design in the era of model-assisted dose-finding.在模型辅助剂量探索时代重新审视等渗相 I 设计。
Clin Trials. 2018 Oct;15(5):524-529. doi: 10.1177/1740774518792258. Epub 2018 Aug 13.
3
Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.多种I期肿瘤学设计的统计操作特征的系统比较。
Contemp Clin Trials Commun. 2016 Nov 24;5:34-48. doi: 10.1016/j.conctc.2016.11.006. eCollection 2017 Mar.
4
Improved up-and-down designs for phase I trials.用于I期试验的改进型上下设计。
Stat Med. 2003 Jan 15;22(1):69-82. doi: 10.1002/sim.1336.
5
Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials.将mTPI和TEQR设计扩展，除毒性外还纳入非单调疗效，以用于肿瘤免疫治疗早期试验的最佳剂量确定。
Contemp Clin Trials Commun. 2018 Jan 31;10:62-76. doi: 10.1016/j.conctc.2018.01.006. eCollection 2018 Jun.
6
2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy.用于确定安全有效最佳剂量的二维（2D）TEQR设计。
Contemp Clin Trials Commun. 2019 Oct 12;16:100461. doi: 10.1016/j.conctc.2019.100461. eCollection 2019 Dec.
7
Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.基于贝叶斯区间的肿瘤剂量递增设计，采用重复准连续毒性模型。
Contemp Clin Trials. 2021 Mar;102:106265. doi: 10.1016/j.cct.2021.106265. Epub 2021 Jan 5.
8
A Likelihood Perspective on Dose-Finding Study Designs in Oncology.
Pharm Stat. 2025 Mar-Apr;24(2):e2445. doi: 10.1002/pst.2445. Epub 2024 Dec 18.
9
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范（2023年）]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
10
Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology.当前肿瘤学中具有毒性和疗效的早期剂量探索设计的统计操作特征。
J Biopharm Stat. 2024 Nov 16:1-21. doi: 10.1080/10543406.2024.2424845.
引用本文的文献
1
Isotonic Phase I cancer clinical trial design utilizing patient-reported outcomes.利用患者报告结局的等渗I期癌症临床试验设计
Stat Biopharm Res. 2025;17(1):36-45. doi: 10.1080/19466315.2023.2288013. Epub 2024 Jan 5.
2
Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose.基于改良等渗回归的 I/II 期临床试验设计，确定最佳生物学剂量。
Contemp Clin Trials. 2023 Apr;127:107139. doi: 10.1016/j.cct.2023.107139. Epub 2023 Mar 2.
3
A Brief Overview of Adaptive Designs for Phase I Cancer Trials.I期癌症试验适应性设计概述
Cancers (Basel). 2022 Mar 18;14(6):1566. doi: 10.3390/cancers14061566.
4
TSNP: A two-stage nonparametric phase I/II clinical trial design for immunotherapy.TSNP：一种免疫治疗的两阶段非参数 I/II 期临床试验设计。
Pharm Stat. 2021 Mar;20(2):282-296. doi: 10.1002/pst.2075. Epub 2020 Oct 6.
5
Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.用于多种毒性的新型准连续终点的剂量发现设计。
Stat Med. 2013 Jul 20;32(16):2728-46. doi: 10.1002/sim.5737. Epub 2013 Jan 21.
6
Interplay of priors and skeletons in two-stage continual reassessment method.两阶段连续再评估方法中先验和骨架的相互作用。
Stat Med. 2012 Dec 30;31(30):4321-36. doi: 10.1002/sim.5559. Epub 2012 Aug 15.
7
Estimating the dose-toxicity curve in completed phase I studies.估算已完成的 I 期研究中的剂量-毒性曲线。
Stat Med. 2011 Jul 30;30(17):2117-29. doi: 10.1002/sim.4206. Epub 2011 Feb 22.
8
Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach.具有单调目标函数的连续和有序结果的剂量确定：一种统一方法。
Biometrics. 2009 Mar;65(1):307-15. doi: 10.1111/j.1541-0420.2008.01045.x. Epub 2008 May 13.
本文引用的文献
1
Escalation, group and A + B designs for dose-finding trials.剂量探索试验的剂量递增、分组及A+B设计。
Stat Med. 2006 Nov 15;25(21):3668-78. doi: 10.1002/sim.2470.
2
Isotonic designs for phase I cancer clinical trials with multiple risk groups.针对具有多个风险组的I期癌症临床试验的等渗设计。
Clin Trials. 2004;1(6):499-508. doi: 10.1191/1740774504cn058oa.
3
Bivariate isotonic design for dose-finding with ordered groups.用于有序组剂量探索的双变量等渗设计
Stat Med. 2006 Jun 30;25(12):2018-26. doi: 10.1002/sim.2312.
4
Designs for single- or multiple-agent phase I trials.单药或多药I期试验的设计。
Biometrics. 2004 Sep;60(3):661-9. doi: 10.1111/j.0006-341X.2004.00215.x.
5
A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.二维剂量探索试验设计与分析的非参数方法
Stat Med. 2004 Jun 30;23(12):1861-70. doi: 10.1002/sim.1796.
6
Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials.用于I期癌症临床试验的传统基于算法设计的统计特性。
Biostatistics. 2001 Jun;2(2):203-15. doi: 10.1093/biostatistics/2.2.203.
7
Improved up-and-down designs for phase I trials.用于I期试验的改进型上下设计。
Stat Med. 2003 Jan 15;22(1):69-82. doi: 10.1002/sim.1336.
8
Isotonic designs for phase I trials.I期试验的等渗设计。
Control Clin Trials. 2001 Apr;22(2):126-38. doi: 10.1016/s0197-2456(00)00132-x.
9
Continual reassessment method: a practical design for phase 1 clinical trials in cancer.连续重新评估法：癌症一期临床试验的实用设计
Biometrics. 1990 Mar;46(1):33-48.
Zotero 插件